Association of primary tumor radiomic phenotypes and outcomes in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) treated with cytoreductive nephrectomy (CN).

被引：0
|
作者：
Cunha, Mateus Trinconi
Stangler, Lucas
Freire, Pedro
Alves Pinto, Paulo Victor
Almeida Coelho, Fernando Morbeck
Viana, Publio
Cordeiro, Mauricio
Nahas, William Carlos
Mota, Jose Mauricio
机构：
[1] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Radiol, Sao Paulo, Brazil
[3] Univ Sao Paulo, Dept Radiol, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[4] Univ Sao Paulo, Dept Urol, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
622
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Wood, C. G.
    Corn, P. G.
    Jonasch, E.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
    Ghatalia, Pooja
    Handorf, Elizabeth A.
    Deng, Mengying
    Zibelman, Matthew R.
    Abbosh, Philip
    Anari, Fern
    Greenberg, Richard E.
    Viterbo, Rosalia
    Chen, David
    Smaldone, Marc C.
    Kutikov, Alexander
    Geynisman, Daniel M.
    Uzzo, Robert Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Cytoreductive nephrectomy in primary metastatic clear cell renal cell carcinoma
    Beisland, Christian
    SCANDINAVIAN JOURNAL OF UROLOGY, 2020, 54 (06) : 500 - 500
  • [4] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Matin, S. F.
    Wood, C. G.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
    Finelli, A.
    Horgan, A. M.
    Evans, A.
    Kim, T. K.
    Durrant, K.
    Yap, S.
    Cassol, C. A.
    Dubinski, W.
    Fleshner, N.
    Jewett, M. A. S.
    Joshua, A. M.
    Sridhar, S. S.
    Zlotta, A.
    Knox, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
    Chakiryan, Nicholas H.
    Gore, L. Robert
    Reich, Richard R.
    Dunn, Rodney L.
    Jiang, Da David
    Gillis, Kyle A.
    Green, Elizabeth
    Hajiran, Ali
    Hugar, Lee
    Zemp, Logan
    Zhang, Jingsong
    Jain, Rohit K.
    Chahoud, Jad
    Spiess, Philippe E.
    Manley, Brandon J.
    Sexton, Wade J.
    Hollenbeck, Brent K.
    Gilbert, Scott M.
    JAMA NETWORK OPEN, 2022, 5 (05)
  • [8] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04) : E709 - E710
  • [9] The comparison of cytoreductive nephrectomy (CN) with tyrosine kinase inhibitor therapy alone in patients with primary metastatic renal cell carcinoma (mRCC).
    Hatakeyama, Shingo
    Naito, Sei
    Numakura, Kazuyuki
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Kandori
    Tsushima, Eiki
    Nishiyama, Hiroyuki
    Ito, Akihiro
    Kojima, Yoshiyuki
    Habuchi, Tomonori
    Obara, Wataru
    Tsuchiya, Norihiko
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345